Valuation dashboard for Biofrontera Inc. (BFRI) with P/E N/A, P/B 2.78, EV/EBITDA -4.17 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Analysis Summary
Biofrontera Inc. reported revenue of $41.7M in the most recent fiscal year, growing at a 5-year CAGR of 17.2%.
Trailing-twelve-month margins: gross margin 84.5%, operating margin -9.5%, net margin -13.8%.
At the current price of $1.21, BFRI has negative trailing earnings (P/E not meaningful) and an ROE of -127.78%. Market capitalisation stands at $15M.
Balance sheet quality for BFRI: current ratio of 1.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.78 |
| EV / EBITDA | -4.17 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-30.68 |
| vs Current Price | -2635.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BFRI | Biofrontera Inc. | $15M | 2.78 | -127.8% | |
| RPRX | Royalty Pharma plc | $25.9B | 24.26 | 3.81 | 12.3% |
| CORT | Corcept Therapeutics Incorporated | $12.1B | 207.35 | 16.10 | 8.4% |
| 0I3Q.L | Corcept Therapeutics Incorporated | $11.7B | 217.89 | 16.92 | 8.4% |
| LQDA | Liquidia Corporation | $6.1B | 42.09 | 30.09 | |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.9B | 72.84 | 9.24 | 13.7% |
| 0HF9.L | Amicus Therapeutics, Inc. | $5.3B | 19.37 | -12.0% | |
| PBH | Prestige Consumer Healthcare Inc. | $2.2B | 13.34 | 1.19 | 9.2% |
Price
| Price | $1.21 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -127.78% |
| Return on Invested Capital | -31.18% |
| Return on Assets | -26.45% |
| Gross Margin | 84.45% |
| Operating Margin | -9.45% |
| Net Margin | -13.78% |
Related companies: AYTU · COCP · DWTX · EVGN · GELS · IMNN · PRPH
Explore sector: Healthcare · Medical - Pharmaceuticals
More sections of BFRI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks